Everolimus (Everolimus) Patent Expiration, LOE Window & CMS Spending

Everolimus (Everolimus) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 17 AB generics, $227.7M 2024 CMS Part D & Medicaid spend, and $13,556 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors17
2024 CMS Total Public Spend$227.7M
2024 Medicare Part D Spend$143.5M
2024 Medicaid Spend$84.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($13,556 intro WAC)